

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier, and a protein consisting of a deglycosylated kringle 1-3 region fragment of a plasminogen protein, ~~and, optionally, a protein consisting of a naturally glycosylated kringle 1-3 region fragment of a plasminogen protein~~, wherein the deglycosylated kringle 1-3 region fragment lacks one or more carbohydrate moieties linked to naturally glycosylated forms of the fragment, and wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, ~~and wherein the amount of the naturally glycosylated kringle 1-3 region fragment present in the composition is smaller than the amount of the deglycosylated kringle 1-3 region fragment present in the composition~~.
2. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a bisialylated-biantennary glycan.
3. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks an N-linked carbohydrate moiety.
4. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a carbohydrate chain at amino acid position corresponding to the N-glycosylation site of human plasminogen.
5. (Cancelled)
6. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment begins at approximately amino acid 87 of human plasminogen.
7. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

8. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

9. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has an amino acid substitution at amino acid position corresponding to the N-glycosylation site of human plasminogen.

10. (Currently Amended) The composition of claim 4 29, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of at least 60:40.

11. (Currently Amended) The composition of claim 4 29, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of at least 80:20.

12. (Currently Amended) The composition of claim 4 29, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of 100:0.

13-14 (Cancelled)

15. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

16. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

17-26 (Cancelled)

27. (Previously Presented) A deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

28. (Cancelled)

29. (New) The composition of claim 1, further comprising a protein consisting of a naturally glycosylated kringle 1-3 region fragment of a plasminogen protein,

wherein the amount of the naturally glycosylated kringle 1-3 region fragment present in the composition is smaller than the amount of the deglycosylated kringle 1-3 region fragment present in the composition.

30. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment lacks a bisialylated-biantennary glycan.

31. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment lacks an N-linked carbohydrate moiety.

32. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment lacks a carbohydrate chain at amino acid position corresponding to the N-glycosylation site of human plasminogen.

33. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment begins at approximately amino acid 87 of human plasminogen.

34. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

35. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

36. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment has an amino acid substitution at amino acid position corresponding to the N-glycosylation site of human plasminogen.

37. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

38. (New) The composition of claim 29, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.